Creo Medical, the UK medical device maker, reported first-half 2026 revenue of £3.2 million, representing a 45% increase compared with the same period a year earlier. The company also achieved a 15% reduction in operating costs over the six-month span and said it had lowered its operating loss by more than 25%.
Management attributed the top-line improvement to stronger adoption of its therapeutic device range, specifically naming Speedboat, SpydrBlade Flex and MicroBlate Fine as contributors to the revenue uplift. The company additionally highlighted geographic expansion efforts, with particular mention of new market activity in Latin America as supporting growth.
On the cost side, Creo Medical said it reduced expenditures by scaling back its commercial platform, streamlining business operations, and outsourcing certain manufacturing activities. These measures contributed to the 15% decline in operating costs and the greater-than-25% reduction in the operating loss reported for the half.
Management reaffirmed the company’s full-year revenue growth guidance of 50% to 60%. Executives pointed to a strong order book and a revenue profile that is weighted toward the second half of the year as supporting the maintained outlook.
The company also noted that its lower cost base, in combination with recent financing, will help move the business toward profitability. No additional financial details on the financing were provided in the announcement.
Operational context
The updates emphasize both demand-side drivers - increased product adoption and regional expansion - and supply-side measures - simplified operations and outsourced manufacturing - as the twin levers behind the half-year performance. Management continues to signal that a disproportionate share of revenue is expected in the latter half of the year, underpinned by the current order book.
Outlook and near-term focus
Creo Medical has maintained its full-year revenue growth guidance and is positioning its reduced cost structure and recent financing as enablers of a move toward profitability. The company’s prospects for meeting guidance will depend on execution in the second half and the conversion of orders into revenue.